Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

FLUVOXAMINE MALEATE

All products: general benefit

Other products in the same Health Canada class (N06A, N06AB) — coverage varies; not interchangeable

  • Citalopram (Celexa): general benefit, Not a benefit
  • Escitalopram (Cipralex MELTZ): general benefit, Not a benefit
  • Fluoxetine (Prozac): general benefit, Not a benefit
  • Paroxetine (Paxil): general benefit, Not a benefit
  • Sertraline (Zoloft): general benefit
  • Amitriptyline (Elavil): general benefit

17 more in the class list below

Luvox · DIN 01919342 · 50mg · tablet

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Luvox (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Luvox · DIN 01919342 Manufacturer: BGP Pharma ULC; listing date 1996-10-01 Health Canada: Marketed since 2017-01-09 · brand LUVOX · ATC N06AB08 FLUVOXAMINE · form Tablet · route Oral · ingredients FLUVOXAMINE MALEATE 50 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.5410 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11752 · Verify on the e-Formulary ↗ (DIN 01919342)

Source record
DIN 01919342: Luvox Raw flags: sec3=Y Item: 281604058; group id 462; item number 1159; lccId None; manufacturer id BGP Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $1.1489; ministry $0.5410 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01919342 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11752
Interchangeable products
Apo-Fluvoxamine · DIN 02231329 · $0.5410 Teva-Fluvoxamine · DIN 02255529 · $0.5410
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (28:16:04 Antidepressants) and how they are covered

Matched class: 28:16:04 Antidepressants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMITRIPTYLINE, CLOMIPRAMINE HCL, NORTRIPTYLINE, PHENELZINE SULFATE, SERTRALINE HCL, TRANYLCYPROMINE SULFATE, VENLAFAXINE HCL, VORTIOXETINE HYDROBROMIDE Some products covered without a code (check the product listing): CITALOPRAM HYDROBROMIDE, DESIPRAMINE, DOXEPIN HCL, DULOXETINE, ESCITALOPRAM, FLUOXETINE HCL, IMIPRAMINE, MIRTAZAPINE, MOCLOBEMIDE, PAROXETINE HCL, TRAZODONE HYDROCHLORIDE, TRIMIPRAMINE 28:16:04 Antidepressants

CITALOPRAM HYDROBROMIDE

· 51 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (42) · strengths: 10mg, 20mg, 40mg · Tab

ESCITALOPRAM

· 40 products · Listed, not a benefit (2), General benefit (38) · strengths: 10mg, 20mg · Orally Disintegrating Tab, Orally Disintegrating Tablet, Tab

FLUOXETINE HCL

· 41 products · Off-Formulary Interchangeable, not an ODB benefit (17), Listed, not a benefit (2), General benefit (22) · strengths: 10mg, 20mg, 40mg, 60mg, 20mg/5mL · Cap, Oral Sol

PAROXETINE HCL

· 47 products · Off-Formulary Interchangeable, not an ODB benefit (16), General benefit (31) · strengths: 10mg, 20mg, 30mg · Tab

SERTRALINE HCL

· 49 products · General benefit · strengths: 25mg, 50mg, 100mg · Cap

AMITRIPTYLINE

· 12 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

CLOMIPRAMINE HCL

· 5 products · General benefit · strengths: 25mg, 50mg, 10mg · Tab

DESIPRAMINE

· 7 products · Listed, not a benefit (4), General benefit (3) · strengths: 25mg, 50mg, 75mg · Tab

DOXEPIN HCL

· 20 products · General benefit (12), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Cap

DULOXETINE

· 38 products · Listed, not a benefit (2), General benefit (36) · strengths: 30mg, 60mg · DR Cap

IMIPRAMINE

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 10mg, 25mg, 50mg · Tab

MIRTAZAPINE

· 25 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 15mg, 30mg, 45mg · Orally Disintegrating Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:04 and 12 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: depression, obsessive-compulsive disorder
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: CLOMIPRAMINE HCL, SERTRALINE HCL CLOMIPRAMINE HCL · General benefit 1 INDICATIONS ANAFRANIL (clomipramine hydrochloride tablets) is indicated for: • the treatment of depression. PM: https://pdf.hres.ca/dpd_pm/00070452.PDF; date SEP 28, 2020; DIN 00324019; fetched 2026-09-10 Product monograph FLUOXETINE HCL · Off-Formulary Interchangeable, not an ODB benefit (17), Listed, not a benefit (2), General benefit (22) • Obsessive-Compulsive Disorder (OCD): pms-FLUOXETINE is indicated for the symptomatic treatment of obsessive-compulsive disorder (OCD). PM: https://pdf.hres.ca/dpd_pm/00076968.PDF; date AUG 30, 2024; DIN 02177579; fetched 2026-09-10 Product monograph SERTRALINE HCL · General benefit Therefore, the health professional who elects to use ZOLOFT for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient.  Obsessive-Compulsive Disorder ZOLOFT is indicated for the symptomatic relief of obsessive-compulsive disorder (OCD). PM: https://pdf.hres.ca/dpd_pm/00072140.PDF; date AUG 22, 2023; DIN 01962779; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS LUVOX® (fluvoxamine maleate) is indicated for:  Depression:  LUVOX® may be indicated for the symptomatic relief of depressive illness in adults.  The effectiveness of LUVOX® in long-term use (i.e., for more than 5 to 6 weeks) has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use LUVOX® for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.  Obsessive-Compulsive Disorder:  LUVOX® has been shown to significantly reduce the symptoms of obsessive-compulsive disorder in adults. The obsessions or compulsions must be experienced as intrusive, markedly distressing, time consuming, or interfering significantly with the person's social or occupational functioning.  The efficacy of LUVOX® has been studied in double-blind, placebo-controlled clinical trials conducted in obsessive-compulsive outpatients. The usefulness of LUVOX® for long-term use (i.e. for more than 10 weeks) has not been systematically evaluated in controlled tri… https://pdf.hres.ca/dpd_pm/00062197.PDF PM date: JAN 9, 1991 Source product: LUVOX; DIN 01919342; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.